

Canaan

Wende Hutton

General Partner / West Coast
Since 2004

Wende identifies, builds and invests in companies that can change the practice of medicine by bringing novel drugs, technologies and devices to market. She joined Canaan in 2004 and throughout her career she has partnered with founders to deliver more than a dozen of those innovations to patients. Her track record includes seven IPOs and six acquisitions.

Wende currently sits on the boards of Antiva Biosciences, Chrono Therapeutics, Glooko, OncoResponse and Hyalex Orthopaedics. Her prior investments include BiPar Sciences (acquired by Sanofi-Aventis), Chimerix (CMRX), Dermira (DERM), Labrys Biologics (acquired by Teva Pharmaceutical) and Transcend Medical (acquired by Alcon/Novartis). Wende was recognized among Fierce Biotech's 2014 "Fierce 15" women in biotech.

Wende was previously a General Partner at Mayfield. Earlier in her career, Wende held senior marketing and business development roles at GenPharm International and Nellcor. Wende spends her free time volunteering with global health and conservation organizations. She holds a B.A. in human biology from Stanford University and an M.B.A. from Harvard Business School.

About Canaan

Canaan is an early stage venture capital firm that invests in entrepreneurs with visionary ideas. With \$5B under management, a diversified fund and over 190 exits to date, Canaan has invested in some of the world's leading technology and healthcare companies over the past 30 years. Canaan's focus areas include fintech, enterprise/cloud, marketplaces, frontier tech, biopharma, digital health and medtech. To learn more about our people and our portfolio, please visit canaan.com.